{"entity":{"id":"mrna-lnp-manufacturing","kind":"technology","name":"mRNA and lipid nanoparticle manufacturing","aka":[],"tldr":"An mRNA cancer vaccine is made without cells: a DNA template is copied into RNA by an enzyme in a tank, cleaned up, and wrapped in tiny fat bubbles. For personalised vaccines the whole run is done once for each patient, against that patient's own tumour mutations, in a few weeks.","summary":"mRNA manufacture begins with a plasmid DNA template (covered in the plasmid record), which is linearised and transcribed in vitro by T7 RNA polymerase with a cap analogue and modified nucleotides. The RNA is purified by tangential flow filtration and chromatography (oligo-dT affinity, and reverse-phase or cellulose steps that remove the double-stranded RNA that triggers unwanted inflammation), then mixed with an ionisable lipid, a phospholipid, cholesterol and a PEG-lipid in a microfluidic or T-junction mixer so lipid nanoparticles self-assemble around it. The particles are buffer-exchanged, sterile-filtered, filled and frozen. Every step is cell-free, which is why COVID-19 vaccines could be scaled in months, and the same enzymes, cap analogues, lipids and single-use mixers are the supply chain for cancer vaccines.\n\nPersonalised neoantigen vaccines change the logistics. For intismeran autogene (mRNA-4157, Moderna with Merck) the tumour and blood are sequenced, up to thirty-four neoantigens are chosen by algorithm, a patient-specific plasmid is made and the RNA and nanoparticle steps are run as a single-patient GMP batch, with a turnaround of weeks; Moderna produces these at its Norwood, Massachusetts, site and has built a dedicated individualised therapy facility in Marlborough. BioNTech makes autogene cevumeran in Mainz on a similar cycle. Constraints are ionisable lipid patents and supply, enzyme and cap analogue suppliers, and the per-patient release testing that has to be as fast as the manufacture. A Phase 3 trial in melanoma (with pembrolizumab) and trials in lung and pancreatic cancer will decide whether this factory model is worth industrialising.","status":"phase-3","asOf":"2026-09-17","links":[{"label":"FDA guidance: CMC information for human gene therapy INDs","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/MRNA_vaccine"}],"tags":["manufacturing-wave"],"related":[],"cancers":["melanoma","pancreatic","nsclc"],"sections":["immunotherapy"],"technologies":["plasmid-dna-manufacturing","neoantigen-mrna-vaccine","single-use-bioprocessing","sterile-fill-finish","cell-therapy-cold-chain","shared-antigen-vaccine"],"targets":[],"drugs":["intismeran-autogene","autogene-cevumeran"],"companies":["moderna","biontech","merck","aldevron","touchlight","thermo-fisher","lonza"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo manufacturing expansion","editedOn":"2026-09-17"},"principle":"Cell-free enzymatic synthesis of RNA from a DNA template, purified and encapsulated in self-assembling lipid nanoparticles; personalised products run the whole chain once per patient.","strengths":["No cell culture, so weeks not months","Sequence can change without changing the process","Same platform for shared and personalised antigens"],"limitations":["Cold chain at minus 20 or minus 70 degrees","Lipid and enzyme supply and patents","Per-patient release testing must keep pace"],"since":2020},"route":"/technologies/mrna-lnp-manufacturing/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"cell-therapy-cold-chain","kind":"technology","name":"Cryopreservation and cell-therapy cold chain","route":"/technologies/cell-therapy-cold-chain/"},{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"},{"id":"plasmid-dna-manufacturing","kind":"technology","name":"Plasmid DNA and mRNA raw-material manufacturing","route":"/technologies/plasmid-dna-manufacturing/"},{"id":"single-use-bioprocessing","kind":"technology","name":"Single-use bioprocessing systems","route":"/technologies/single-use-bioprocessing/"},{"id":"sterile-fill-finish","kind":"technology","name":"Sterile fill-finish and lyophilisation","route":"/technologies/sterile-fill-finish/"}],"drug":[{"id":"autogene-cevumeran","kind":"drug","name":"Autogene cevumeran","route":"/drugs/autogene-cevumeran/"},{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/"}],"company":[{"id":"aldevron","kind":"company","name":"Aldevron (Danaher)","route":"/companies/aldevron/"},{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"},{"id":"lonza","kind":"company","name":"Lonza","route":"/companies/lonza/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"},{"id":"moderna","kind":"company","name":"Moderna","route":"/companies/moderna/"},{"id":"thermo-fisher","kind":"company","name":"Thermo Fisher Scientific","route":"/companies/thermo-fisher/"},{"id":"touchlight","kind":"company","name":"Touchlight","route":"/companies/touchlight/"}]}}